Login to save this article and read it later.
(CercleFinance.com) – Sanofi shares gain 1% in Paris while earlier today UBS reaffirmed its buy recommendation on the stock with an adjusted target price of 99 to 101 euros, implying a potential 25% increase for the stock, after the last investor day of the French healthcare giant.
The broker said in the summary of its note: « General drugs are not the usual focus of attention, but a new explicit sales target for 2025 implies an increase in consensus estimates in the medium term ».
Copyright (c) 2021 Cercle Finance. The information and analyses disseminated by Cercle Finance are only a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analysis by readers. It is recommended to any uninformed person to consult a professional adviser before any investment. This indicative information does not constitute in any way an incitement to sell or a solicitation to buy.
101 euros at 3 months in reverse will be difficult.